Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma - Wikidata - awgldk - TriplyDB

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

http://www.wikidata.org/entity/Q57950969

about

Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases Pretreatment Serum Lactate Dehydrogenase and N Classification Predict Long-Term Survival and Distant Metastasis in Patients With Nasopharyngeal Carcinoma Who Have A Positive Family History of Cancer.Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma.Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma Current and emerging treatment options for nasopharyngeal carcinoma.Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index of Overall Survival in Cisplatin-based Chemotherapy-treated Patients with Metastatic Nasopharyngeal Carcinoma.Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).Circulating biomarkers for gliomas.Investigational drugs for nasopharyngeal carcinoma.Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: A meta-analysis.Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients.EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model.The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma.Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma.Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone: a retrospective study.The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma.Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.Liquid Biopsy in Head and Neck Cancer: Promises and Challenges.

P2860

Q26823898-CA4A5D09-1618-4C40-8C4B-5454490CBC69 Q28274789-08730935-66BB-42FE-9649-EAC6261CBA97 Q33411816-D34CA6CF-3417-4015-9838-A14DD3345FCC Q34286259-5028A18F-168E-44E3-AA83-80F24D92A72A Q35326653-124E9387-CB45-4BAF-BF0A-445E074EA904 Q35619542-12641CD2-1D94-4E39-A118-575D73C0EB3B Q36152889-3D909799-0272-44A6-8B8B-093456B50EB9 Q36256111-B2628E30-2136-4992-BD08-47B6A0BADCC1 Q36305182-089FCE47-F7CA-458E-B9E6-06303506C424 Q36335515-F391A852-1C9E-4F2E-A3E5-2AD704EFAAAE Q36359374-03213F9F-27B1-4F96-BAA9-9A2484E8DF5F Q36628563-E189A108-1A4E-49E3-8837-55702D4FE3D6 Q36687528-6ED5999B-6570-419E-A2E1-11B8F8BCDB5F Q37086039-0C517DF4-A420-4EF6-B5B7-26C97A504A44 Q37175573-23F84B0E-2DA4-46CA-AD6C-4837E0291C83 Q37248002-9C2BD684-81F0-4E71-B32D-658FADC8E49C Q37353950-B996FCE3-667D-42D7-BB7F-C747D98876FF Q37564699-5A5EEAC5-F960-4F3D-BCF5-554F61C0A61D Q37705026-3DE4D701-3120-4B2F-A4D4-B7215DB152A2 Q37738086-8C1C20E8-CAFE-4CFD-B24A-ECB7D49C2041 Q38270678-3DD467B0-0858-472C-8E95-5D40D84D0AC5 Q38385856-E51978D4-E689-4AD3-A5F5-383B9DCC6DD7 Q38586617-58A42715-E433-4A7E-855A-62DBFA90FA2F Q38690528-F219E1B5-C0B2-4595-BF8F-7CCB0891E6C5 Q38982843-037A248A-50A0-4EAD-8A1F-7B66E5493F8A Q39054753-25A351A9-C347-42F6-B59E-269F394226AA Q39652489-91A98AF9-173B-46A3-A32D-D51A973F5DD2 Q41093379-06064ED3-ED95-44C9-BD82-BBEF9439ACB6 Q41757247-505A98B3-85A7-4591-B954-29264B0556A3 Q42145376-C6DF0A6B-6CF8-4532-A3F2-712E828116D7 Q42230815-7D58F4E8-2201-41B8-97AB-BB3019FE3726 Q42375480-D49574B1-9F3D-42D6-8993-60A9268DA4E8 Q45351163-2493FB13-4FDC-4C9E-932E-08CBA13D4B82 Q45361755-BC101204-C512-4A6D-94AF-59F9986DEEEA Q45369099-A7886680-8AFB-438B-ADA9-2796A3EB3CFC Q52647899-E862E0AC-7FFD-415A-B5C0-FBC953C7C8C5 Q52669514-A0B8E73D-E46F-48AA-A8F9-A6C8BBDF383A

P2860

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

http://www.wikidata.org/entity/Q57950969

description

article

@en

im Januar 2010 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2010

@uk

name

Plasma EBV DNA Clearance Rate ...... rrent Nasopharyngeal Carcinoma

@en

Plasma EBV DNA Clearance Rate ...... rrent Nasopharyngeal Carcinoma

@nl

type

label

Plasma EBV DNA Clearance Rate ...... rrent Nasopharyngeal Carcinoma

@en

Plasma EBV DNA Clearance Rate ...... rrent Nasopharyngeal Carcinoma

@nl

prefLabel

Plasma EBV DNA Clearance Rate ...... rrent Nasopharyngeal Carcinoma

@en

Plasma EBV DNA Clearance Rate ...... rrent Nasopharyngeal Carcinoma

@nl

P1433

Q57950969-753A837B-B3E3-45BF-A20C-D23A420D35A8

P1476

Q57950969-2C155D29-3AEA-4EED-8A74-BFE8F7B813D8

P2093

Q57950969-028D9CCD-7E33-49C4-BA34-352C58D5EE87

Q57950969-034D25EC-757A-4315-BF9B-4E9DAF4A5D95

Q57950969-25B056C4-C89D-4A4B-8332-EACE3736F0D1

Q57950969-380D3949-8575-43C2-9538-7AD5DCCA939D

Q57950969-3ADDF9D6-63BB-4398-ADC9-72F8AFA9082F

Q57950969-8065FF04-B7E7-40E0-B39E-BFF7D2CC60EA

Q57950969-C11DB68E-6BA5-4877-B9C5-60C377767E52

Q57950969-CFD25405-5791-4E52-B3F4-B3782B01F7A3

Q57950969-D5628FDF-5981-4EEA-B977-4DB0E5B5740D

P304

Q57950969-BDF84078-862A-48D8-9805-9006BE6933DB

P31

Q57950969-7B7D8CE2-70B9-47C6-928B-0EF0F3706531

P356

Q57950969-3325BF36-6E6A-4D23-B654-3C72636D6A40

P407

Q57950969-6513BA43-44E3-438E-9B8E-B3939F471841

P433

Q57950969-49FCE2F4-5598-424C-A6F1-12C4DEC22A45

P478

Q57950969-256C8EE8-70EE-4394-93E6-002D1E171586

P50

Q57950969-9BF2F619-F140-402A-B978-45A2148E4F0D

P577

Q57950969-19FE0569-4ED8-47EA-835F-0BA33DD6ED95

P698

Q57950969-CC187CEA-E35B-4796-A12B-E0864E75717B

P356

1078-0432.CCR-09-2796

P1433

Clinical Cancer Research

P1476

Plasma EBV DNA clearance rate ...... rrent nasopharyngeal carcinoma

@en

P2093

Chih-Wen Twu

http://www.w3.org/2001/XMLSchema#string

Ching-Te Wu

http://www.w3.org/2001/XMLSchema#string

Hsin-Hong Chen

http://www.w3.org/2001/XMLSchema#string

Jeffrey Y C Chao

http://www.w3.org/2001/XMLSchema#string

Jian-Sheng Jan

http://www.w3.org/2001/XMLSchema#string

Jin-Ching Lin

http://www.w3.org/2001/XMLSchema#string

Kai-Li Liang

http://www.w3.org/2001/XMLSchema#string

Kuan-Wen Chen

http://www.w3.org/2001/XMLSchema#string

Wen-Yi Wang

http://www.w3.org/2001/XMLSchema#string

P304

1016-1024

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2796

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20103659

http://www.w3.org/2001/XMLSchema#string